Article Text

other Versions

Download PDFPDF
Longitudinal (18F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation
  1. Rhian S Convery1,
  2. Jieqing Jiao2,
  3. Mica T M Clarke1,
  4. Katrina M Moore1,
  5. Carolin A M Koriath1,
  6. Ione O C Woollacott1,
  7. Philip S J Weston1,
  8. Roger Gunn3,
  9. Ilan Rabiner3,
  10. David M Cash1,
  11. Martin N Rossor1,
  12. Jason D Warren1,
  13. Nick C Fox1,4,
  14. Sebastien Ourselin2,
  15. Martina Bocchetta1,
  16. Jonathan D Rohrer1
  1. 1Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
  2. 2School of Biomedical Engineering and Imaging Sciences, King's College London, London, London, UK
  3. 3Imanova Centre for Imaging Sciences, London, UK
  4. 4Dementia Research Institute at UCL, London, UK
  1. Correspondence to Dr Jonathan D Rohrer, Dementia Research Centre, UCL Institute of Neurology, London WC1N 3BG, UK; j.rohrer{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Mutations in the microtubule associated protein tau (MAPT) gene are a common cause of inherited frontotemporal dementia (FTD) and result in the deposition of pathological tau protein in the brain.1 Tau positron emission tomography (PET) may enhance in vivo diagnosis and testing of tau-based therapies in FTD, however, few tau ligands have been validated in FTD. The (18F)AV-1451 ligand was developed to assess in vivo tau accumulation and has consistently been shown to bind to tau in individuals with Alzheimer’s disease (AD) but less work has focused on the non-AD tauopathies, including FTD. Autoradiography studies of (18F)AV-1451 have shown strong binding in regions of neurofibrillary tangles matching the pattern of paired helical filament (PHF) immunochemistry but have not shown strong binding to non-PHF-tau.2

In (18F)AV-1451 studies conducted in FTD spectrum disorders, not only does the ligand not bind strongly to non-PHF tau, but there is significant in vivo binding reported in conditions where no tau is expected at all, for example, in patients with semantic variant primary progressive aphasia and with C9orf72 expansions where TDP-43 pathology is usually found.3 4 (18F)AV-1451 also displays both off-target binding in the basal ganglia and an age-related increase in binding in cognitively healthy controls.3 Nevertheless, this ligand has shown strong binding in a subset of FTD-causing MAPT mutations, including V337M and R406W that are associated with PHF-tau pathology.1 5 (18F)AV-1451 may therefore be useful in detecting tau pathology in some genetic forms of FTD that result in similar structural conformations of tau to that of AD. Here we describe longitudinal (18F)AV-1451 PET imaging from a patient with FTD due to a Q351R mutation located on exon 12 of the MAPT gene.6



A patient with a Q351R MAPT mutation in her mid-60s as …

View Full Text


  • Contributors JDR, RC and JJ designed this study, analysed the data and wrote the manuscript. MC, KM, CK, IOCW, PW, RG, IR, DC, MR, JDW, NCF, SO and MB helped with data collection, analysis and review of the manuscript.

  • Funding The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit and the NIHR UCL/H Biomedical Research Centre, the MRC UK GENFI grant (MR/M023664/1) and the Alzheimer’s Society (AS-PG-16-007). This work was conducted using the MRC Dementias Platform UK (MR/L023784/1 and MR/009076/1). JDR is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). JDW was supported by a Wellcome Trust Senior Clinical Fellowship (091673/Z/10/Z) and his research is supported by the Alzheimer’s Society, Alzheimer’s Research UK and by the NIHR UCLH Biomedical Research Centre. NCF acknowledges support from the UK Dementia Research Institute at UCL. IOCW was funded by an MRC Clinical Research Training Fellowship (MR/M018288/1). Research Councils UK > Medical Research Council 520874.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by the local ethics committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.